Literature DB >> 18083217

Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling.

G Mangili1, M Petrone, C Gentile, P De Marzi, R Viganò, E Rabaiotti.   

Abstract

OBJECTIVE: Palmar-plantar erythrodysesthesia (PPE) is a characteristic cutaneous toxicity associated with pegylated liposomal doxirubicin (PLD). Different therapies have been proposed to alleviate PPE onset. We performed a prospective study to evaluate preventive strategies to reduce PPE incidence in patients treated for gynecologic cancers.
METHODS: Fifty-three patients were treated from 2001 to 2006 with PLD as single agent therapy or in combination with carboplatin or paclitaxel. PLD dosages were in the range of 30-50 mg/m2 every 21-28 days. All patients received premedication with dexamethasone and pyridoxine. Twenty-eight patients received application of ice packs on extremities during PLD infusion.
RESULTS: PPE was observed in 11 patients (20.8%). PLD administration as single agent or in combination and schedule of PLD therapy did not affect PPE incidence. A significant reduction in PPE onset was observed if PLD dosage was 30-35 mg/m2 (p=0.03) and when patients were submitted to regional cooling protocol (p=0.0097).
CONCLUSIONS: The use of ice packs around wrists and ankles is a simple and well tolerated prevention strategy and its efficacy is demonstrated in this study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18083217     DOI: 10.1016/j.ygyno.2007.10.021

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  16 in total

1.  Cytarabine and Doxorubicin-Induced Palmoplantar Erythrodysesthesia Syndrome: The Possible Role of Voriconazole Interaction.

Authors:  Maria Tavakoli-Ardakani; Shirin Haghighi; Shervin Shokouhi; Bahareh Abtahi-Naeini; Mohsen Meidani; Rezvan Hassanpour; Ali Saffaei
Journal:  Eurasian J Med       Date:  2019-10

2.  [Hand-foot syndrome with tyrosine kinase inhibitor therapy: treatment recommendations].

Authors:  G J Burbach; T Zuberbier
Journal:  Urologe A       Date:  2013-11       Impact factor: 0.639

3.  Erythrodysesthesia: An Unusual Complication With Trastuzumab Monotherapy.

Authors:  Andee L Fontenot; Weldon J Furr; Ammar Husan; Muhammad W Khan
Journal:  Cureus       Date:  2021-11-30

Review 4.  Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials.

Authors:  Lígia Traldi Macedo; Joao Paulo Nogueira Lima; Lucas Vieira dos Santos; Andre Deeke Sasse
Journal:  Support Care Cancer       Date:  2014-01-26       Impact factor: 3.603

5.  Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer.

Authors:  Seiko Bun; Mayu Yunokawa; Yoshiko Tamaki; Akihiko Shimomura; Tatsunori Shimoi; Makoto Kodaira; Chikako Shimizu; Kan Yonemori; Yasuhiro Fujiwara; Yoshinori Makino; Hiroyuki Terakado; Kenji Tamura
Journal:  Support Care Cancer       Date:  2018-01-25       Impact factor: 3.603

6.  The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia.

Authors:  M Kanis; J P Kesterson; S Lele
Journal:  Eur J Gynaecol Oncol       Date:  2009       Impact factor: 0.196

Review 7.  Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia: a literature review of pharmaceutical and clinical aspects.

Authors:  Yao Zhu; Fenfen Wang; Yunchun Zhao; Xiaoling Zheng
Journal:  Eur J Hosp Pharm       Date:  2020-06-26

Review 8.  Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.

Authors:  Theresa A Lawrie; Andrew Bryant; Alison Cameron; Emma Gray; Jo Morrison
Journal:  Cochrane Database Syst Rev       Date:  2013-07-09

9.  Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment.

Authors:  Katherina Podlekareva Farr; Akmal Safwat
Journal:  Case Rep Oncol       Date:  2011-04-11

10.  The effectiveness of regional cooling for paclitaxel-induced peripheral neuropathy.

Authors:  Junya Sato; Megumi Mori; Satoru Nihei; Masumi Kumagai; Satoshi Takeuchi; Masahiro Kashiwaba; Kenzo Kudo
Journal:  J Pharm Health Care Sci       Date:  2016-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.